Giant Cell Tumor of Bone
📧 Sign up to get email alerts when something new happens for Giant Cell Tumor of Bone.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
Authorised new medicine Bilprevda (denosumab) by Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone and bone neoplasms.
-
EMA approval · 2026-08-24EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH
Bomyntra (denosumab) has been authorised by the EMA for indications related to bone neoplasms including Giant Cell Tumor of Bone; MAH is Fre…
-
EMA approval · 2026-08-18EMA Authorised: Yaxwer (denosumab) — Gedeon Richter Plc.
EMA authorised Yaxwer (denosumab) by Gedeon Richter Plc. for neoplasms involving bone tissue, including giant cell tumor of bone.
-
EMA approval · 2026-08-13EMA Authorised: Osenvelt (denosumab) — Celltrion Healthcare Hungary Kft.
EMA has authorised Osenvelt (denosumab) for Giant Cell Tumor of Bone and related bone neoplasms.
-
EMA approval · 2026-07-14EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
Authorised status for Bilprevda (denosumab) in the European Union for Giant Cell Tumor of Bone and Neoplasms of Bone Tissue.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-10EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorises Bomyntra (denosumab) for therapeutic areas including neoplasms of bone tissue and giant cell tumor of bone.
-
EMA approval · 2026-07-08EMA Authorised: Wyost (denosumab) — Sandoz GmbH
The EMA authorises Wyost (denosumab) by Sandoz GmbH for indications in Giant Cell Tumor of Bone and other bone neoplasms.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone [Phase 3]
This entry reports a Phase 3 clinical trial evaluating the effect of local bisphosphonates on recurrence rates in extremity giant cell tumor…
-
EMA approval · 2026-04-16EMA Authorised: Enwylma — Zentiva k.s.
The EMA authorised Enwylma from Zentiva k.s. for neoplasms of bone tissue, including giant cell tumor of bone, with the decision dated 15 Ap…
-
EMA approval · 2026-03-27EMA Authorised: Vevzuo (denosumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Vevzuo, a denosumab biosimilar, for bone neoplasms including Giant Cell Tumor of Bone.
-
EMA approval · 2026-03-19EMA Authorised: Xgeva (denosumab) — Amgen Europe B.V.
European Medicines Agency authorised Xgeva (denosumab) for giant cell tumor of bone, expanding its indications for this bone neoplasm. Decis…
-
EMA approval · 2026-03-19EMA Authorised: Osenvelt (denosumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Osenvelt (denosumab) by Celltrion Healthcare Hungary Kft. for Giant Cell Tumor of Bone and other bone neoplasms.
-
EMA approval · 2026-03-02EMA Authorised: Xbonzy (denosumab) — Reddy Holding GmbH
The EMA authorised Xbonzy (denosumab) by Reddy Holding GmbH for the treatment of giant cell tumor of bone and other bone neoplasms.
-
EMA approval · 2026-01-20EMA Authorised: Degevma (denosumab) — Teva GmbH
EMA authorised Degevma (denosumab) by Teva GmbH for Giant Cell Tumor of Bone, expanding treatment options for this rare bone neoplasm.
-
EMA approval · 2026-01-14EMA Authorised: Zvogra (denosumab) — Stada Arzneimittel AG
The EMA authorised Zvogra (denosumab) for the treatment of giant cell tumor of bone and bone neoplasms.
-
EMA approval · 2026-01-09EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
The EMA authorised Bilprevda (denosumab) from Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone. This expands denosumab's use to bone ne…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery [Phase 4]
A Phase 4 clinical trial is evaluating the accuracy of indocyanine green fluorescence imaging to assist Giant cell tumor of bone surgery.
-
EMA approval · 2025-11-24EMA Authorised: Denbrayce (denosumab) — Mabxience Research SL
The EMA has authorised Denbrayce (denosumab) from Mabxience Research SL for the treatment of giant cell tumor of the bone. The product targe…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas [Phase 2]
Phase 2 study of LN-145 (LN-145-S1) in relapsed or refractory ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, oste…
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: PROMIS and Mobility Evaluation in Sarcoma Patients
A clinical trial is evaluating PROMIS and mobility in sarcoma patients and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone [Phase 4]
This clinical trial update notes that a Phase 4 study of XGEVA (denosumab) in Chinese adults and skeletally mature adolescents with giant ce…
-
EMA approval · 2025-09-17EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH
The European Medicines Agency authorised Bomyntra (denosumab) by Fresenius Kabi Deutschland GmbH for neoplasms of bone tissue, including gia…
-
EMA approval · 2025-09-08EMA Authorised: Yaxwer (denosumab) — Gedeon Richter Plc.
EMA authorised Yaxwer (denosumab) by Gedeon Richter for the treatment of giant cell tumor of bone in the European Union.
-
EMA approval · 2025-08-13EMA Authorised: Wyost (denosumab) — Sandoz GmbH
The European Medicines Agency authorised Wyost, a denosumab medicine from Sandoz GmbH, for Giant Cell Tumor of Bone and related bone neoplas…
-
EMA approval · 2025-07-28EMA Authorised: Jubereq (denosumab) — Accord Healthcare S.L.U.
EMA authorised Jubereq (denosumab) from Accord Healthcare S.L.U. for the treatment of Giant cell tumor of bone and other bone neoplasms.